Lysogene S.A. (LYSGF)
- Business Wire
Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
PARIS, May 18, 2022--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provided updated clinical data from the ongoing AAVance phase 2/3 clinical trial with the investigational gene therapy LYS-SAF302 for the treatment of MPS IIIA (NCT03612869) during the 25th Annual Meeting of the ASGCT (American Society for Gene & Cell Therapy) in Washington, DC.
- Business Wire
Lysogene Reports its Cash Position as of 31 March 2022
PARIS, April 28, 2022--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its cash position of €10.7 million1 as of 31 March 2022 (compared to €12.3 million as of 31 December 2021).
- Business Wire
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
PARIS, April 21, 2022--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today the publication of a peer-reviewed article in EMBO Molecular Medicine (Habbas et al., EMBO Mol Med (2022) e14649) showing that adeno-associated viral (AAV) vector-delivered diacylglycerol kinase (DGKk) achieves long-term rescue of fragile X syndrome (FXS) in a mouse model of disease.
